138 related articles for article (PubMed ID: 35017657)
1. The antibody response of haematological malignancies to COVID-19 infection and vaccination.
Seebacher NA
Br J Cancer; 2022 Mar; 126(5):691-692. PubMed ID: 35017657
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of the BNT162b2 COVID-19 mRNA vaccine and early clinical outcomes in patients with haematological malignancies in Lithuania: a national prospective cohort study.
Maneikis K; Šablauskas K; Ringelevičiūtė U; Vaitekėnaitė V; Čekauskienė R; Kryžauskaitė L; Naumovas D; Banys V; Pečeliūnas V; Beinortas T; Griškevičius L
Lancet Haematol; 2021 Aug; 8(8):e583-e592. PubMed ID: 34224668
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of COVID-19 vaccine response in patients with cancer: An interim analysis.
Tran S; Truong TH; Narendran A
Eur J Cancer; 2021 Dec; 159():259-274. PubMed ID: 34798454
[TBL] [Abstract][Full Text] [Related]
4. Blunted humoral response after mRNA vaccine in patients with haematological malignancies.
Kamboj M
Lancet Haematol; 2021 Aug; 8(8):e540-e542. PubMed ID: 34224666
[No Abstract] [Full Text] [Related]
5. COVID-19 vaccines for patients with haematological conditions.
Sun C; Pleyer C; Wiestner A
Lancet Haematol; 2021 May; 8(5):e312-e314. PubMed ID: 33811822
[No Abstract] [Full Text] [Related]
6. Impact of Therapy in Patients with Hematologic Malignancies on Seroconversion Rates After SARS-CoV-2 Vaccination.
Guven DC; Sahin TK; Akın S; Uckun FM
Oncologist; 2022 Apr; 27(4):e357-e361. PubMed ID: 35274729
[TBL] [Abstract][Full Text] [Related]
7. Therapy in Patients with Hematologic Malignancies, Seroconversion Rates, and SARS-CoV-2 Vaccination.
Sriwijitalai W; Wiwanitkit V
Oncologist; 2022 Nov; 27(11):e916. PubMed ID: 36018054
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.
Lee ARYB; Wong SY; Chai LYA; Lee SC; Lee MX; Muthiah MD; Tay SH; Teo CB; Tan BKJ; Chan YH; Sundar R; Soon YY
BMJ; 2022 Mar; 376():e068632. PubMed ID: 35236664
[TBL] [Abstract][Full Text] [Related]
9. BNT162b2 COVID-19 vaccine is significantly less effective in patients with hematologic malignancies.
Herzog Tzarfati K; Gutwein O; Apel A; Rahimi-Levene N; Sadovnik M; Harel L; Benveniste-Levkovitz P; Bar Chaim A; Koren-Michowitz M
Am J Hematol; 2021 Oct; 96(10):1195-1203. PubMed ID: 34185336
[TBL] [Abstract][Full Text] [Related]
10. T-cell immune response after mRNA SARS-CoV-2 vaccines is frequently detected also in the absence of seroconversion in patients with lymphoid malignancies.
Marasco V; Carniti C; Guidetti A; Farina L; Magni M; Miceli R; Calabretta L; Verderio P; Ljevar S; Serpenti F; Morelli D; Apolone G; Ippolito G; Agrati C; Corradini P
Br J Haematol; 2022 Feb; 196(3):548-558. PubMed ID: 34649298
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity of the COVID-19 Two-Vaccination Series Among Hematologic Malignancies: Report of Three Cases of Breakthrough Infection.
Pasikhova Y; Morrison AR; Katzman JH; Syed M
Cancer Control; 2022; 29():10732748211070720. PubMed ID: 35001670
[TBL] [Abstract][Full Text] [Related]
12. Reasons and consequences of COVID-19 vaccine failure in patients with chronic lymphocytic leukemia.
Morawska M
Eur J Haematol; 2022 Feb; 108(2):91-98. PubMed ID: 34717004
[TBL] [Abstract][Full Text] [Related]
13. Seroconversion and outcomes after initial and booster COVID-19 vaccination in adults with hematologic malignancies.
Ollila TA; Masel RH; Reagan JL; Lu S; Rogers RD; Paiva KJ; Taher R; Burguera-Couce E; Zayac AS; Yakirevich I; Niroula R; Barth P; Olszewski AJ
Cancer; 2022 Sep; 128(18):3319-3329. PubMed ID: 35811461
[TBL] [Abstract][Full Text] [Related]
14. Analysis of antibody responses after COVID-19 vaccination in liver transplant recipients and those with chronic liver diseases.
Thuluvath PJ; Robarts P; Chauhan M
J Hepatol; 2021 Dec; 75(6):1434-1439. PubMed ID: 34454993
[TBL] [Abstract][Full Text] [Related]
15. The use of vaccines to safeguard patients with haematological malignancies.
Sekkides O
Lancet Infect Dis; 2019 Jun; 19(6):572. PubMed ID: 30744960
[No Abstract] [Full Text] [Related]
16. Third dose of COVID-19 vaccine restores immune response in patients with haematological malignancies after loss of protective antibody titres.
Šušol O; Hájková B; Zelená H; Hájek R
Br J Haematol; 2022 May; 197(3):302-305. PubMed ID: 35076937
[TBL] [Abstract][Full Text] [Related]
17. Factors that predict severity of infection and seroconversion in immunocompromised children and adolescents with COVID-19 infection.
Abu Shanap M; Sughayer M; Alsmadi O; Elzayat I; Al-Nuirat A; Tbakhi A; Sultan I
Front Immunol; 2022; 13():919762. PubMed ID: 35990639
[TBL] [Abstract][Full Text] [Related]
18. Doctor-Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders.
Živković SA; Gruener G; Narayanaswami P;
Muscle Nerve; 2021 Mar; 63(3):294-303. PubMed ID: 33471383
[TBL] [Abstract][Full Text] [Related]
19. COVID-19 vaccination in immunocompromised patients.
Sonani B; Aslam F; Goyal A; Patel J; Bansal P
Clin Rheumatol; 2021 Feb; 40(2):797-798. PubMed ID: 33426632
[No Abstract] [Full Text] [Related]
20. Cancer or COVID-19? A Review of Recommendations for COVID-19 Vaccination in Cancer Patients.
Gundavda MK; Gundavda KK
Curr Treat Options Oncol; 2021 Sep; 22(10):95. PubMed ID: 34515857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
